Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.
Level V
Where this comes from
- Record sourced from PubMed, PMID 23287454.
- Also identified by DOI 10.1161/CIRCRESAHA.111.300271 and PMC identifier 3572712.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck.
Medical subject headings
- Blood Platelets
- Cardiovascular Diseases
- Cyclooxygenase Inhibitors
- Drug Discovery
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Translational Research, Biomedical